Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dovramilast - Amgen

Drug Profile

Dovramilast - Amgen

Alternative Names: AMG-634; CC-11050

Latest Information Update: 08 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Medicines Development for Global Health
  • Class Amides; Anti-inflammatories; Cyclopropanes; Isoindoles; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leprosy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Leprosy; Tuberculosis

Most Recent Events

  • 03 Nov 2023 Dovramilast - Amgen receives Orphan Drug status for Leprosy in USA
  • 22 Dec 2020 AMG 634 licensed to Medicines Development for Global Health worldwide
  • 22 Jun 2020 Amgen plans phase II clinical trial in Tuberculosis in 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top